Karyopharm Therapeutics Inc

18 sie 2026, 20:03 UTC

Karyopharm Therapeutics Inc is trading higher today, continuing its upward trend since Monday's close. The stock remains below its 20-day moving average.

17 sie 2026, 23:46 UTC

Karyopharm Therapeutics shares are higher in after-market hours, following volatility earlier. Broader market pressures include geopolitical tensions and rising crude oil prices.

14 sie 2026, 23:51 UTC

Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.

13 sie 2026, 23:11 UTC

Karyopharm Therapeutics Inc shares are rising in after-market trading, showing a modest upward trend since Thursday's close despite recent significant declines.

12 sie 2026, 19:56 UTC

Karyopharm Therapeutics Inc shares are lower today, retracing from an early high amid broader market conditions and geopolitical tensions. No specific news was identified.

11 sie 2026, 20:01 UTC

Karyopharm Therapeutics Inc is trading higher today, having reached a peak earlier in the session. The stock remains below its 20-day moving average.

10 sie 2026, 20:06 UTC

Karyopharm Therapeutics Inc shares are lower today, reversing an early gain and reaching a mid-morning low, with no specific news identified for the decline.

7 sie 2026, 23:31 UTC

Karyopharm Therapeutics shares are lower in after-market hours, following a decline earlier despite gains in major tech stocks. No specific news was identified.

6 sie 2026, 23:21 UTC

Karyopharm Therapeutics Inc shares are lower in after-market hours. The asset is trading below its 20-day moving average and near the lower end of its one-month range.

5 sie 2026, 23:01 UTC

Karyopharm Therapeutics shares are lower in after-market hours, continuing a three-session decline amid broader market weakness from disappointing U.S. employment data.

4 sie 2026, 23:46 UTC

Karyopharm Therapeutics shares are higher in after-market trading, though no specific news explains the movement. Broader market optimism may be influencing risk assets.

3 sie 2026, 23:41 UTC

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

1 sie 2026, 00:01 UTC

Karyopharm Therapeutics Inc shares are higher in after-market hours, reaching their highest cumulative return of the day despite recent underperformance.

31 lip 2026, 23:31 UTC

Karyopharm Therapeutics shares rose during after-market hours, continuing a recovery from an earlier low. The stock remains below its 20-day moving average.

30 lip 2026, 23:41 UTC

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

29 lip 2026, 19:27 UTC

Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.

27 lip 2026, 19:07 UTC

Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.

24 lip 2026, 19:42 UTC

Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.

23 lip 2026, 09:01 UTC

Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.

22 lip 2026, 18:41 UTC

Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.

21 lip 2026, 20:12 UTC

Karyopharm Therapeutics shares are lower in after-market hours, with no specific news driving the decline despite positive sentiment in U.S. markets.

20 lip 2026, 23:01 UTC

Karyopharm Therapeutics shares fell in after-market hours following the announcement of a leadership cash retention program aimed at key executives.